{"title":"马来西亚私营部门干细胞产业的神话与现实","authors":"Kean Chang Phang, Mohammad Firdaus Bin Abdul Aziz","doi":"10.1007/s41649-024-00330-4","DOIUrl":null,"url":null,"abstract":"<div><p>Notwithstanding its potential medical benefits, there are unproven stem cell–based therapies being offered across the globe. Little is known about the landscape of Malaysia’s private stem cell sector of which this study aims to explore. Qualitative study was conducted to explore its status through empirical interviews with stakeholders in the private sector. This study reveals that private researchers face with limited funding and overwhelming bureaucracies resulting in a low output. There is also a lack of governance for stem cell therapy, and some concerns over how stem cell–based therapies are being offered. Hence, urgent interventions by regulatory authorities are vital to ensure ethical and safe clinical practices in the private sector to protect the reputation of this promising industry.\n</p></div>","PeriodicalId":44520,"journal":{"name":"Asian Bioethics Review","volume":"17 4","pages":"729 - 752"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Myths and Realities about the Private Sector Stem Cell Industry in Malaysia\",\"authors\":\"Kean Chang Phang, Mohammad Firdaus Bin Abdul Aziz\",\"doi\":\"10.1007/s41649-024-00330-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Notwithstanding its potential medical benefits, there are unproven stem cell–based therapies being offered across the globe. Little is known about the landscape of Malaysia’s private stem cell sector of which this study aims to explore. Qualitative study was conducted to explore its status through empirical interviews with stakeholders in the private sector. This study reveals that private researchers face with limited funding and overwhelming bureaucracies resulting in a low output. There is also a lack of governance for stem cell therapy, and some concerns over how stem cell–based therapies are being offered. Hence, urgent interventions by regulatory authorities are vital to ensure ethical and safe clinical practices in the private sector to protect the reputation of this promising industry.\\n</p></div>\",\"PeriodicalId\":44520,\"journal\":{\"name\":\"Asian Bioethics Review\",\"volume\":\"17 4\",\"pages\":\"729 - 752\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Bioethics Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s41649-024-00330-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ETHICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Bioethics Review","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s41649-024-00330-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ETHICS","Score":null,"Total":0}
Myths and Realities about the Private Sector Stem Cell Industry in Malaysia
Notwithstanding its potential medical benefits, there are unproven stem cell–based therapies being offered across the globe. Little is known about the landscape of Malaysia’s private stem cell sector of which this study aims to explore. Qualitative study was conducted to explore its status through empirical interviews with stakeholders in the private sector. This study reveals that private researchers face with limited funding and overwhelming bureaucracies resulting in a low output. There is also a lack of governance for stem cell therapy, and some concerns over how stem cell–based therapies are being offered. Hence, urgent interventions by regulatory authorities are vital to ensure ethical and safe clinical practices in the private sector to protect the reputation of this promising industry.
期刊介绍：
Asian Bioethics Review (ABR) is an international academic journal, based in Asia, providing a forum to express and exchange original ideas on all aspects of bioethics, especially those relevant to the region. Published quarterly, the journal seeks to promote collaborative research among scholars in Asia or with an interest in Asia, as well as multi-cultural and multi-disciplinary bioethical studies more generally. It will appeal to all working on bioethical issues in biomedicine, healthcare, caregiving and patient support, genetics, law and governance, health systems and policy, science studies and research. ABR provides analyses, perspectives and insights into new approaches in bioethics, recent changes in biomedical law and policy, developments in capacity building and professional training, and voices or essays from a student’s perspective. The journal includes articles, research studies, target articles, case evaluations and commentaries. It also publishes book reviews and correspondence to the editor. ABR welcomes original papers from all countries, particularly those that relate to Asia. ABR is the flagship publication of the Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore. The Centre for Biomedical Ethics is a collaborating centre on bioethics of the World Health Organization.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
